Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working—and which may not.